Literature DB >> 4031500

Protective monoclonal antibody against Schistosoma mansoni: antigen isolation, characterization, and suitability for active immunization.

R T Hazdai, F Levi-Schaffer, V Brenner, S Horowitz, Z Eshhar, R Arnon.   

Abstract

Monoclonal antibodies that bind to the surface of developing schistosomula were generated from the spleens of chronically infected mice that were boosted with cercarial glycoproteins. The two most reactive monoclonal antibodies, denoted 152-66-9B and 152-66-1C, were used for identification of surface antigens. The antigen detected by these monoclonal antibodies persisted on the surface of the developing larva for 72 hr posttransformation. This monoclonal antibody effected complement-mediated killing of schistosomula in vitro as efficiently as infected mouse sera. It was also very efficient in inhibiting the infectivity of both cercariae and schistosomula. The antigen reactive with the 152-66-9B monoclonal antibody contains two major polypeptides (45 and 30 KD). These polypeptide chains might have originated from the same protein, because they have the same isoelectric point in two-dimensional gel electrophoresis. Moreover, the affinity-purified antigen migrated as only one protein band of approximately 200 KD in SDS-PAGE in nonreducing conditions. The 9B antigen was isolated, purified, and used for immunization, resulting in an antigen dose-dependent partial protection against S. mansoni infection.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4031500

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  4 in total

1.  Intranasal administration of synthetic recombinant peptide-based vaccine protects mice from infection by Schistosoma mansoni.

Authors:  T Ben-Yedidia; R Tarrab-Hazdai; D Schechtman; R Arnon
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

2.  Synthesis and characterization of a protective peptide-based vaccine against Schistosoma mansoni.

Authors:  R Tarrab-Hazdai; D Schechtman; R Arnon
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

3.  A mimotope peptide-based vaccine against Schistosoma mansoni: synthesis and characterization.

Authors:  R Arnon; R Tarrab-Hazdai; M Steward
Journal:  Immunology       Date:  2000-12       Impact factor: 7.397

4.  Candidate vaccine antigens identified by antibodies from mice vaccinated with 15- or 50-kilorad-irradiated cercariae of Schistosoma mansoni.

Authors:  D Richter; D A Harn
Journal:  Infect Immun       Date:  1993-01       Impact factor: 3.441

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.